Zelluna ASA ZLNA
OSL · Norway · Health Technology
NOK 20.40+0.50 (+2.51%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Oslo, 20 August 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the second quarter 2026. Webcast scheduled for 20 August 2026 at 09:00 (CEST). Link to webcast here. Operational Highlights: First patient dosed with ZI-MA4-1: On 13 July 2026, Zelluna announced the dosing of the first patient in the Phase 1 ZIMA-101 study, marking
Independent Data Monitoring Committee (IDMC) recommends recruitment of the next two patients at the first dose levelFirst patient completed the planned first treatment cycle with no serious adverse events or dose-limiting toxicities observedStudy progressing as planned following favourable initial safety review 17 August 2026 – Zelluna ASA (OSE: ZLNA) today announced that the Independent Data Monitoring Committee (IDMC) has completed its review of the first patient’s safety data from the first-i
Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new member of the Company’s Board of Directors (the “Board”). The Nomination Committee has proposed Martin Welschof for election as a new member of the Board. Martin Welschof is CEO of BioInvent International AB (Nasdaq Stockholm) and has previously served as CEO of Affitech A/S and Opsona Therapeutics.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.